Search

Your search keyword '"Song, Eyun"' showing total 202 results
Start Over Author "Song, Eyun"
202 results on '"Song, Eyun"'

8. Ischaemic stroke in patients with diabetes requiring urgent procedures during the COVID-19 pandemic in South Korea: a retrospective, nationwide, population-based cohort study using data from the National Emergency Department Information System

Author

Park, Min Jeong, primary, Hwang, Jeongeun, additional, Ahn, Jonghwa, additional, Park, Sung Joon, additional, Song, Eyun, additional, Jang, Ahreum, additional, Choi, Kyung Mook, additional, Baik, Sei Hyun, additional, and Yoo, Hye Jin, additional

Published
2023
Full Text
View/download PDF

18. Comparison of Laser and Conventional Lancing Devices for Blood Glucose Measurement Conformance and Patient Satisfaction in Diabetes Mellitus

Author

Kim, Jung A, primary, Park, Min Jeong, additional, Song, Eyun, additional, Roh, Eun, additional, Park, So Young, additional, Lee, Da Young, additional, Kim, Jaeyoung, additional, Yu, Ji Hee, additional, Seo, Ji A, additional, Choi, Kyung Mook, additional, Baik, Sei Hyun, additional, Yoo, Hye Jin, additional, and Kim, Nan Hee, additional

Published
2022
Full Text
View/download PDF

25. Treatment Modality and Risk of Heart Failure in Patients With Long-Standing Graves’ Disease: A Nationwide Population-Based Cohort Study

Author

Song, Eyun, primary, Kim, Mina, additional, Park, Sojeong, additional, Park, Min Jeong, additional, Kim, Jung A., additional, Roh, Eun, additional, Yu, Ji Hee, additional, Kim, Nam Hoon, additional, Seo, Ji A., additional, Kim, Sin Gon, additional, Kim, Nan Hee, additional, Choi, Kyung Mook, additional, Baik, Sei Hyun, additional, and Yoo, Hye Jin, additional

Published
2021
Full Text
View/download PDF

30. Effect of Metabolic Health and Obesity Phenotype on the Risk of Pancreatic Cancer: A Nationwide Population-Based Cohort Study

Author

Chung, Hye Soo, primary, Lee, Ji Sung, additional, Song, Eyun, additional, Kim, Jung A, additional, Roh, Eun, additional, Yu, Ji Hee, additional, Kim, Nam Hoon, additional, Yoo, Hye Jin, additional, Seo, Ji A, additional, Kim, Sin Gon, additional, Kim, Nan Hee, additional, Baik, Sei Hyun, additional, and Choi, Kyung Mook, additional

Published
2021
Full Text
View/download PDF

36. Association between urinary sodium levels and iodine status in Korea

Author

Ahn, Jonghwa, primary, Lee, Jang Ho, additional, Lee, Jiwoo, additional, Baek, Ji Yeon, additional, Song, Eyun, additional, Oh, Hye-Seon, additional, Kim, Mijin, additional, Park, Suyeon, additional, Jeon, Min Ji, additional, Kim, Tae Yong, additional, Kim, Won Bae, additional, Shong, Young Kee, additional, and Kim, Won Gu, additional

Published
2020
Full Text
View/download PDF

38. Evidence for genetic heterogeneity in lymphedema-cholestasis syndrome

Author

Frühwirth, Martin, Janecke, Andreas R., Müller, Thomas, Carlton, Victoria E.H., Kronenberg, Florian, Offner, Felix, Knisely, A. S., Geleff, Silvana, Song, Eyun J., Simma, Burkhard, Königsrainer, Alfred, Margreiter, Raimund, van der Hagen, C. B., Eiklid, Kristin, Aagenaes, Øystein, Bull, Laura, and Ellemunter, Helmut

Published
2003

42. Modified risk stratification based on cervical lymph node metastases following lobectomy for papillary thyroid carcinoma

Author

Song, Eyun, primary, Ahn, Jonghwa, additional, Song, Dong Eun, additional, Kim, Won Woong, additional, Jeon, Min Ji, additional, Sung, Tae‐Yon, additional, Kim, Tae Yong, additional, Chung, Ki Wook, additional, Kim, Won Bae, additional, Shong, Young Kee, additional, Hong, Suck Joon, additional, Lee, Yu‐Mi, additional, and Kim, Won Gu, additional

Published
2019
Full Text
View/download PDF

46. Lobectomy Is Feasible for 1–4 cm Papillary Thyroid Carcinomas: A 10-Year Propensity Score Matched-Pair Analysis on Recurrence

Author

Song, Eyun, primary, Han, Minkyu, additional, Oh, Hye-Seon, additional, Kim, Won Woong, additional, Jeon, Min Ji, additional, Lee, Yu-Mi, additional, Kim, Tae Yong, additional, Chung, Ki Wook, additional, Kim, Won Bae, additional, Shong, Young Kee, additional, Hong, Suck Joon, additional, Sung, Tae-Yon, additional, and Kim, Won Gu, additional

Published
2019
Full Text
View/download PDF

48. The value of preoperative antithyroidperoxidase antibody as a novel predictor of recurrence in papillary thyroid carcinoma

Author

Song, Eyun, primary, Oh, Hye‐Seon, additional, Jeon, Min Ji, additional, Chung, Ki Wook, additional, Hong, Suck Joon, additional, Ryu, Jin Sook, additional, Baek, Jung Hwan, additional, Lee, Jeong Hyun, additional, Kim, Won Gu, additional, Kim, Won Bae, additional, Shong, Young Kee, additional, and Kim, Tae Yong, additional

Published
2018
Full Text
View/download PDF

49. Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Candidate Biomarkers Associated with Survival: A Multicenter Study in Korea.

Author

Song, Eyun, Kim, Mijin, Kim, Eui Young, Kim, Bo Hyun, Shin, Dong Yeob, Kang, Ho-Cheol, Ahn, Byeong-Cheol, Kim, Won Bae, Shong, Young Kee, Jeon, Min Ji, and Lim, Dong Jun

Subjects
*THYROID cancer, *IODINE isotopes, *PROGRESSION-free survival, *BIOMARKERS, *TUMOR growth
Abstract

Background: Lenvatinib, an oral multikinase inhibitor, is the latest addition to the treatment options for radioactive iodine (RAI)-refractory progressive differentiated thyroid carcinoma (DTC). This study investigated the efficacy of lenvatinib in real-world practice and prognostic biomarkers of survival. Methods: This multicenter study included 43 patients receiving lenvatinib as first-line or second-line treatment after sorafenib for RAI-refractory DTC. Progression-free survival (PFS) was evaluated according to various clinical factors including thyroglobulin doubling time (TgDT), tumor volume DT (TVDT), and tumor growth slope (TGS; slope of tumor change rate). Results: Patients were treated with lenvatinib for a median of 14 months; 32 were previously treated with sorafenib. The median follow-up from lenvatinib initiation to the last censoring or death was 16 months. The median starting dose of 20 mg was reduced to a median sustainable dose of 10 mg in accordance with patient adverse events (AEs). The median PFS was 21.8 months; the median overall survival was not reached. The disease control rate was 97.7%, with the first objective response at 3.8 months. PFS was not significantly associated with previous sorafenib treatment, metastatic sites, or sustainable dose. TGS measured before (TGSpre, p = 0.003) and after (TGSpost, p = 0.036) the initiation of lenvatinib was associated with PFS. The sum of the largest diameters of target lesions (p = 0.043) and TgDT (p = 0.024) were associated with PFS, but TVDT calculated before (TVDTpre, p = 0.923) or after (TVDTpost, p = 0.966) lenvatinib treatment did not impact PFS. Lenvatinib was withdrawn in 24 patients (55.8%): in 6 patients because of treatment-induced AEs and in 18 patients because of disease progression or poor performance status. AEs of any grade were reported in all patients, and grade 3–4 AEs in 23.2% of the patients. The most frequent AE was fatigue or asthenia. Conclusions: Our results indicate that reduced doses of lenvatinib triggered by emergent AEs did not abrogate its apparent efficacy in patients with RAI-refractory DTCs. Rather, the sustained use of reduced doses of lenvatinib with a low rate of severe AEs may have contributed to the favorable outcomes. TgDT and TGS can assist in predicting the outcomes in these patients. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

50. Modified risk stratification based on cervical lymph node metastases following lobectomy for papillary thyroid carcinoma.

Author

Song, Eyun, Ahn, Jonghwa, Song, Dong Eun, Kim, Won Woong, Jeon, Min Ji, Sung, Tae‐Yon, Kim, Tae Yong, Chung, Ki Wook, Kim, Won Bae, Shong, Young Kee, Hong, Suck Joon, Lee, Yu‐Mi, and Kim, Won Gu

Subjects
*PAPILLARY carcinoma, *THYROID cancer, *LYMPH nodes, *PROGRESSION-free survival, *METASTASIS
Abstract

Objective: Evidence for American Thyroid Association (ATA) risk stratification stems largely from studies involving patients undergoing total thyroidectomy. We aimed to assess the risk of recurrence according to the present ATA risk stratification system in patients who underwent lobectomy. Design: Retrospective cohort study. Patients: Patients who underwent thyroid lobectomy for 1‐4 cm‐sized papillary thyroid carcinoma (n = 571). Measurements: Disease‐free survival (DFS) was compared according to the ATA risk stratification, and specific lymph node (LN) characteristics were evaluated to modify the ATA criteria with a higher predictability for recurrence. Results: Based on the ATA risk stratification, 439 patients (61.1%) were classified into intermediate‐ or high‐risk group, and consideration for completion thyroidectomy is suggested by ATA guidelines for these patients. However, no significant differences were found in DFS among the low‐, intermediate‐ and high‐risk groups (P =.9). In contrast, when patients were stratified according solely to the LN criteria from the ATA risk stratification, only 127 patients (22.2%) had intermediate risk (intermediate‐N1a) and exhibited significantly poorer DFS than those with N0 disease (P =.035). Modifying the intermediate‐N1a criteria by adding the extranodal extension (ENE) status and omitting the clinical nodal disease enabled the subclassification of 19 patients (3%) with a high risk for recurrence. Conclusions: The present study suggests that risk stratification based solely on LN metastases is more reasonable for predicting structural persistence/recurrence following lobectomy than that based on the overall ATA criteria. Considering the ENE status can assist in selecting patients with a high risk of recurrence to minimize further treatments. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results